Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01503437
Other study ID # BE-170-OLAN-2006
Secondary ID
Status Completed
Phase Phase 1
First received January 2, 2012
Last updated January 4, 2012
Start date November 2006
Est. completion date December 2006

Study information

Verified date January 2012
Source Dr. Reddy's Laboratories Limited
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the single oral dose bioequivalence of olanzapine 5 mg OD tablets with Zyprexa Zydis 5 mg tablets under fasting conditions and to monitor adverse events and ensure safety of subjects.


Description:

An open label, balanced, randomized, two treatment, two-sequence, two-period, single-dose, crossover comparative bioequivalence study of Olanzapine 5 mg OD Tablets, of Dr. Reddy's Laboratories Limited and Zyprexa Zydis 5 mg Tablets of Cardinal Health in healthy, human subjects under fasting conditions.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date December 2006
Est. primary completion date November 2006
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Healthy human subjects within the age range of 18 to 45 years

- Non-smokers since at least six months

- Willingness to provide written informed consent to participate in the study

- Body-mass index of =18.5 kg/m2 and = 24.9 kg/m2, with body weight not less than 50 kg

- Absence of significant disease or clinically significant abnormal laboratory values on laboratory evaluations, medical history or physical examination during the screening

- Normal 12-lead ECG or one with abnormality considered to be clinically insignificant

- Normal chest X-ray PA view

- Comprehension of the nature and purpose of the study and compliance with the requirement of the protocol

- Female Subjects

- of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams. Jellies, diaphragm, intrauterine device (IUD), or abstinence, or

- postmenopausal for at least 1 year, or

- surgically sterile (bilateral tubal ligation. bilateral oophorectomy, or hysterectomy has been performed on the subject

Exclusion Criteria:

- Personal / family history of allergy or hypersensitivity to olanzapine or allied drugs

- Past history of anaphylaxis or angioedema

- Any major illness in the past three months or any clinically significant ongoing chronic medical illness e.g. congestive heart failure, hepatitis, pancreatitis etc.

- Presence of any clinically significant abnormal values during screening e.g. significant abnormality of liver Function Test (LFT), Renal (kidney) Function Test (RFT), etc.

- Any cardiac, renal or liver impairment, any other organ or system impairment

- History of seizure or psychiatric disorders

- Presence of disease markers of HIV 1 and 2, and hepatitis Band C virus

- Consumption of alcohol for more than two years, or consumption of more than three alcoholic drinks per day or consumption of alcohol within 48 hours prior to dosing and during the study [one drink is equal to one unit of alcohol [ one glass Wine, half plnt boor, and one measure (one ounce) of spirit).

- Consumption of xanthine containing derivatives (coffee, tea, cola drinks. chocolate) within 48 hours before check-in of each period

- Use of any recreational drug or a history of drug addiction

- Participation in any clinical trial within the past 3 months

- Inaccessibility of veins in left and right arm

- Donation of blood (one unit or 350 mL) within 3 months prior to receiving the first dose of study medication

- Receipt of any prescription drug therapy within four weeks or over-the-counter (OTC) drugs within two weeks prior to receiving the first dose of study medication or repeated use of drugs Within the last four weeks

- An unusual diet, for whatever reason e.g. low sodium diet, for two weeks prior to receiving any medication and through out subject's participation in the study

- Consumption of grapefruit- containing food or beverages within 7 days prior to receiving the first dose of study medication in both the periods

- Recent history of dehydration from diarrhea, vomiting or any other reason within a period of 24 hours prior to the study

- Female volunteers demonstrating a positive pregnancy screen or currently breast-feeding

- Having an occupation or requirement of driving a vehicle or operate a complex machinery before 21 days of taking the drug in both periods

Study Design

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Olanzapine OD Tablets 5 mg
Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited

Locations

Country Name City State
India Wellquest Clinical Research Mumbai Maharashtra

Sponsors (1)

Lead Sponsor Collaborator
Dr. Reddy's Laboratories Limited

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Bioequivalence is based on Cmax and AUC parameters 2 months No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03754920 - Prolonged Fasting With Meditation and Mild Physical Exercise N/A
Completed NCT05272332 - Gastric Ultrasound Prior to Extubation
Completed NCT04247464 - Short-term Fasting as an Enhancer of Chemotherapy: Pilot Clinical Study on Colorectal Carcinoma Patients N/A
Completed NCT01067001 - Minocycline HCl Extended Release Tablets 135 mg Oral Bioequivalence Study N/A
Completed NCT00757094 - Safety and Feasibility of Fasting While Receiving Chemotherapy N/A
Completed NCT01506713 - Bioequivalence Study of Clopidogrel Tablets 75 mg of Dr. Reddy's Under Fasting Conditions Phase 1
Completed NCT04514380 - Effect of Drinking Carbohydrate-containing Fluids on Gastric Residual Volume in Elderly Patients
Completed NCT05756868 - The Effect of Time-Restricted Feeding on Anthropometry, Biochemical Parameters, Diet Quality and Eating Behavior N/A
Completed NCT05134207 - The Effect of Oral Carbohydrate Solution on Anxiety and Comfort in Patients Undergoing Hip Arthroplasty N/A
Completed NCT05031598 - Long-term Fasting: Multi-system Adaptations in Humans N/A
Recruiting NCT04501393 - Recommended Clear Fluid Intake Volume at 2 Hours Prior to Esophagogastroduodenoscopy for Adult Patients N/A
Enrolling by invitation NCT04027478 - Can Fasting Decrease the Side Effects of Chemotherapy? N/A
Completed NCT05219136 - Improve the Comfort, Safety and Quality of Upper Endoscopy by a Modified Fasting Protocol N/A
Recruiting NCT04625608 - Effect of Premedicant Oral Paracetamol on Gastric Volume and pH Phase 4
Not yet recruiting NCT02562638 - Pre-Procedural Fasting in Cardiac Intervention N/A
Completed NCT01954836 - Short-Term Fasting During Chemotherapy in Patients With Gynecological Cancer- a Randomized Controlled Cross-over Trial N/A
Completed NCT01949987 - Does Oral Intake Decreases Postoperative Pain Score in Children N/A
Completed NCT01713647 - Bioequivalence Study of Amlodipine / Losartan/ Hydrochlorothiazide of PHARMALINE, Lebanon Under Fastion Conditions Phase 1
Completed NCT01831700 - Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fasting Conditions Phase 1
Completed NCT01746719 - Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fasting Condition Phase 1